Article Cited by others

INVITED REVIEW

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer

Stein Mark N, Patel Neal, Bershadskiy Alexander, Sokoloff Alisa, Singer Eric A

Year : 2014| Volume: 16| Issue : 3 | Page no: 387-400

   This article has been cited by
 
1 Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer
Nirmish Singla,Rashed A. Ghandour,Ganesh V. Raj
Expert Opinion on Investigational Drugs. 2019; 28(3): 249
[Pubmed]  [Google Scholar] [DOI]
2 Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Matthew Smith,Chris Parker,Fred Saad,Kurt Miller,Bertrand Tombal,Quan Sing Ng,Martin Boegemann,Vsevolod Matveev,Josep Maria Piulats,Luis Eduardo Zucca,Oleg Karyakin,Go Kimura,Nobuaki Matsubara,William Carlos Nahas,Franco Nolč,Eli Rosenbaum,Axel Heidenreich,Yoshiyuki Kakehi,Amily Zhang,Heiko Krissel,Michael Teufel,Junwu Shen,Volker Wagner,Celestia Higano
The Lancet Oncology. 2019; 20(3): 408
[Pubmed]  [Google Scholar] [DOI]
3 Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group
Joe M. OćSullivan,Joan Carles,Richard Cathomas,Alfonso Gomez-Iturriaga,Daniel Heinrich,Gero Kramer,Piet Ost,Inge van Oort,Bertrand Tombal
European Urology Oncology. 2019;
[Pubmed]  [Google Scholar] [DOI]
4 Targeting of folate-conjugated liposomes with co-entrapped drugs to prostate cancer cells via prostate-specific membrane antigen (PSMA)
Yogita Patil,Hilary Shmeeda,Yasmine Amitay,Patricia Ohana,Saran Kumar,Alberto Gabizon
Nanomedicine: Nanotechnology, Biology and Medicine. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Solubility Measurements at 296 and 310 K and Physicochemical Characterization of Abiraterone and Abiraterone Acetate
Tamás Solymosi,Ferenc Tóth,János Orosz,Orsolya Basa-Dénes,Réka Angi,Tamás Jordán,Zsolt Ötvös,Hristos Glavinas
Journal of Chemical & Engineering Data. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 Determining direct binders of the Androgen Receptor using a high-throughput Cellular Thermal Shift Assay
Joseph Shaw,Mathew Leveridge,Charlotta Norling,Jakob Karén,Daniel Martinez Molina,Daniel O’Neill,James E. Dowling,Paul Davey,Suzanna Cowan,Michael Dabrowski,Martin Main,Davide Gianni
Scientific Reports. 2018; 8(1)
[Pubmed]  [Google Scholar] [DOI]
7 Human cytochrome P450 enzymes 5–51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition – toxic effects and benefits
Slobodan P. Rendic,F. Peter Guengerich
Drug Metabolism Reviews. 2018; 50(3): 256
[Pubmed]  [Google Scholar] [DOI]
8 Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics
Charles F. Polotti,Christopher J. Kim,Nadiya Chuchvara,Alyssa B. Polotti,Eric A. Singer,Sammy Elsamra
Expert Opinion on Drug Metabolism & Toxicology. 2017; 13(12): 1265
[Pubmed]  [Google Scholar] [DOI]
9 Hormone resistance and neuroendocrine differentiation due to accumulation of genetic lesions during clonal evolution of prostate cancer
D. S. Mikhaylenko,G. D. Efremov,A. V. Sivkov,D. V. Zaletaev
Molecular Biology. 2016; 50(1): 28
[Pubmed]  [Google Scholar] [DOI]
10 The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature
Ian M. Bird,David H. Abbott
The Journal of Steroid Biochemistry and Molecular Biology. 2016;
[Pubmed]  [Google Scholar] [DOI]
11 CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Anitha B. Alex,Sumanta K. Pal,Neeraj Agarwal
Therapeutic Advances in Medical Oncology. 2016; 8(4): 267
[Pubmed]  [Google Scholar] [DOI]
12 First results of the double-blind randomized placebo-controlled multicenter clinical trial of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN)
Mikhail Paltsev,Vsevolod Kiselev,Vadim Drukh,Ekaterina Muyzhnek,Igor Kuznetsov,Evgeniya Andrianova,Pavel Baranovskiy
EPMA Journal. 2016; 7(1)
[Pubmed]  [Google Scholar] [DOI]
13 Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Sameer S. Udhane,Bernhard Dick,Qingzhong Hu,Rolf W. Hartmann,Amit V. Pandey
Biochemical and Biophysical Research Communications. 2016;
[Pubmed]  [Google Scholar] [DOI]
14 Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Archana Anantharaman,Terence W. Friedlander
Urologic Oncology: Seminars and Original Investigations. 2015;
[Pubmed]  [Google Scholar] [DOI]
15 Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer
Christopher Sejong Han,Rutveej Patel,Isaac Yi Kim
Expert Opinion on Drug Metabolism & Toxicology. 2015; 11(6): 967
[Pubmed]  [Google Scholar] [DOI]
16 Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibiting cytochrome P450 inhibition: a patent evaluation WO2015048311 (A1)
Richard L Schroeder,Phan Tram,Jiawang Liu,Maryam Foroozesh,Jayalakshmi Sridhar
Expert Opinion on Therapeutic Patents. 2015; : 1
[Pubmed]  [Google Scholar] [DOI]
17 The Steroidogenic Enzyme AKR1C3 Regulates Stability of the Ubiquitin Ligase Siah2 in Prostate Cancer Cells
Lingling Fan,Guihong Peng,Arif Hussain,Ladan Fazli,Emma Guns,Martin Gleave,Jianfei Qi
Journal of Biological Chemistry. 2015; 290(34): 20865
[Pubmed]  [Google Scholar] [DOI]
18 Evolving therapeutic concepts in prostate cancer based on genome-wide analyses (Review)
BJÖRN GEORGI,NINA KORZENIEWSKI,BORIS HADASCHIK,CARSTEN GRÜLLICH,WILFRIED ROTH,HOLGER SÜLTMANN,SASCHA PAHERNIK,MARKUS HOHENFELLNER,STEFAN DUENSING
International Journal of Oncology. 2014; 45(4): 1337
[Pubmed]  [Google Scholar] [DOI]

 

Read this article